Rxsight Valuation
| RXST Stock | USD 9.11 0.11 1.19% |
At this time, the company appears to be overvalued. Rxsight holds a recent Real Value of $8.33 per share. The prevailing price of the company is $9.11. Our model determines the value of Rxsight from analyzing the company fundamentals such as Shares Outstanding of 41.12 M, operating margin of (0.40) %, and Return On Equity of -0.13 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Rxsight's valuation include:
Price Book 1.3737 | Enterprise Value | Enterprise Value Ebitda (7.70) | Price Sales 2.6681 | Forward PE 116.2791 |
Overvalued
Today
Please note that Rxsight's price fluctuation is slightly risky at this time. Calculation of the real value of Rxsight is based on 3 months time horizon. Increasing Rxsight's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Rxsight's intrinsic value may or may not be the same as its current market price of 9.11, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.11 | Real 8.33 | Target 10.5 | Hype 9.11 | Naive 9.97 |
The intrinsic value of Rxsight's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Rxsight's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Rxsight helps investors to forecast how Rxsight stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rxsight more accurately as focusing exclusively on Rxsight's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Rxsight's intrinsic value based on its ongoing forecasts of Rxsight's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Rxsight's closest peers.
Rxsight Cash |
|
Rxsight Revenue by Product
Rxsight Total Value Analysis
Rxsight is at this time projected to have valuation of 163.14 M with market capitalization of 379.1 M, debt of 12.3 M, and cash on hands of 128.62 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rxsight fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
163.14 M | 379.1 M | 12.3 M | 128.62 M |
Rxsight Investor Information
About 82.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.37. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Rxsight has Price/Earnings To Growth (PEG) ratio of 0.03. The entity recorded a loss per share of 0.88. The firm had not issued any dividends in recent years. Based on the key indicators related to Rxsight's liquidity, profitability, solvency, and operating efficiency, Rxsight is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Rxsight Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Rxsight has an asset utilization ratio of 43.92 percent. This implies that the Company is making $0.44 for each dollar of assets. An increasing asset utilization means that Rxsight is more efficient with each dollar of assets it utilizes for everyday operations.Rxsight Profitability Analysis
Based on Rxsight's profitability indicators, Rxsight may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Rxsight's ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -11.8 M | Current Value -9.8 M | Quarterly Volatility 12.2 M |
For Rxsight profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rxsight to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rxsight utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rxsight's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rxsight over time as well as its relative position and ranking within its peers.
Rxsight Earnings per Share Projection vs Actual
By analyzing Rxsight's earnings estimates, investors can diagnose different trends across Rxsight's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Rxsight is based on EPS before non-recurring items and includes expenses related to employee stock options.Rxsight Ownership Allocation
Rxsight owns a total of 41.12 Million outstanding shares. The majority of Rxsight outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rxsight to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rxsight. Please pay attention to any change in the institutional holdings of Rxsight as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Rxsight Profitability Analysis
The company reported the previous year's revenue of 139.93 M. Net Loss for the year was (27.45 M) with profit before overhead, payroll, taxes, and interest of 106.53 M.About Rxsight Valuation
The stock valuation mechanism determines Rxsight's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Rxsight based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Rxsight. We calculate exposure to Rxsight's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rxsight's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 113.8 M | 119.5 M | |
| Pretax Profit Margin | (0.23) | (0.21) | |
| Operating Profit Margin | (0.24) | (0.25) | |
| Net Loss | (0.23) | (0.21) | |
| Gross Profit Margin | 0.64 | 0.67 |
Rxsight Growth Indicators
Investing in growth stocks can be very risky. If the company such as Rxsight does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 38.9 M | |
| Forward Price Earnings | 116.2791 |
Rxsight Current Valuation Indicators
Rxsight's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Rxsight's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Rxsight, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Rxsight's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Rxsight's worth.Additional Tools for Rxsight Stock Analysis
When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.